Key result
Only ~52% of high-volume centers follow recommended Impella heparin purge concentrations.
Why the study?
Managing anticoagulation in patients supported by the Impella pVAD is challenging due to unique device features and lack of standardized strategies, especially for patients with contraindications to UFH.
Cross-Sectional (n=65)
Yes
Answers are grounded in this paper and cite their sources.
Impella anticoagulation practices vary widely among high-volume centers; leaves open optimal regimens and supports prospective outcome trials.
OBJECTIVES: To characterize anticoagulation practices with the Impella percutaneous ventricular assist device (pVAD). BACKGROUND: Managing anticoagulation in patients being supported by the Impella pVAD is made challenging by several unique features of the device. These include the release of a dextrose-based purge solution containing unfractionated heparin (UFH), the need to concurrently administer systemic anticoagulation with intravenous UFH, and the lack of an alternative strategy in patients with contraindications to UFH. METHODS: To characterize anticoagulation practices with the Impella pVAD, we conducted a survey of centers in the United States performing a high volume of Impella cases, which we defined as > 1 per month. Centers were contacted via email or phone and individuals who agreed to participate were provided with a link to complete the survey online. The primary measures of interest were variations in practice across centers and variations from the manufacturer's recommendations. RESULTS: Practices varied considerably among respondents (65 of 182 centers, or 35.7%) and often diverged from manufacturer recommendations. Approximately half of centers (52.4%) reported using a UFH concentration of 50 units/mL in the purge solution, whereas most of the remaining centers (41.3%) reported using lower concentrations. Strategies for the initiation and adjustment of systemic therapy also varied, as did practices for routinely monitoring for hemolysis. Nearly one-fifth of centers (16.7%) had not developed an alternative strategy for the purge solution in patients with contraindications to UFH. Most centers (58.4%) reported using argatroban or bivalirudin in this scenario, a strategy that diverges from the manufacturer's recommendations. CONCLUSIONS: Given these findings, studies to determine a systematic approach to anticoagulation with the Impella device are warranted.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2019) conducted a cross-sectional in Anticoagulation management during Impella support (n=65). Institutional anticoagulation practices during Impella support was evaluated on Variations in practice across centers and variations from the manufacturer's recommendations. Anticoagulation practices for the Impella device varied considerably among high-volume centers, with only 52.4% using the manufacturer-recommended unfractionated heparin concentration.
Synapse has enriched 10 related papers. Consider them for comparative context: